Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more
Qingdao Baheal Medical INC. - Asset Resilience Ratio
Qingdao Baheal Medical INC. (301015) has an Asset Resilience Ratio of 3.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Qingdao Baheal Medical INC.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Qingdao Baheal Medical INC.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥265.39 Million | 3.5% |
| Total Liquid Assets | CN¥265.39 Million | 3.50% |
Asset Resilience Insights
- Limited Liquidity: Qingdao Baheal Medical INC. maintains only 3.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Qingdao Baheal Medical INC. Industry Peers by Asset Resilience Ratio
Compare Qingdao Baheal Medical INC.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950 |
Medical Distribution | 0.00% |
|
Shenzhen Glory Medical Co Ltd
SHE:002551 |
Medical Distribution | 10.46% |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589 |
Medical Distribution | -4.18% |
|
Hanmi Science
KO:008930 |
Medical Distribution | 0.06% |
|
BCM Alliance Bhd
KLSE:0187 |
Medical Distribution | 17.12% |
|
Excelsior Medical Co Ltd
TW:4104 |
Medical Distribution | 3.70% |
|
CHC Healthcare Group
TW:4164 |
Medical Distribution | 0.46% |
|
China Meheco Co Ltd
SHG:600056 |
Medical Distribution | 0.35% |
Annual Asset Resilience Ratio for Qingdao Baheal Medical INC. (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Qingdao Baheal Medical INC..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.63% | CN¥44.99 Million | CN¥7.11 Billion | +0.09pp |
| 2023-12-31 | 0.55% | CN¥28.97 Million | CN¥5.30 Billion | -1.09pp |
| 2022-12-31 | 1.64% | CN¥83.72 Million | CN¥5.12 Billion | +0.53pp |
| 2021-12-31 | 1.11% | CN¥50.95 Million | CN¥4.60 Billion | +0.25pp |
| 2020-12-31 | 0.86% | CN¥34.90 Million | CN¥4.05 Billion | +0.40pp |
| 2018-12-31 | 0.46% | CN¥12.00 Million | CN¥2.63 Billion | -- |